MARKET

RGEN

RGEN

Repligen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

159.17
+4.99
+3.24%
After Hours: 159.17 0 0.00% 16:40 05/26 EDT
OPEN
155.36
PREV CLOSE
154.18
HIGH
160.00
LOW
154.00
VOLUME
428.14K
TURNOVER
0
52 WEEK HIGH
327.32
52 WEEK LOW
137.21
MARKET CAP
8.82B
P/E (TTM)
63.07
1D
5D
1M
3M
1Y
5Y
Repligen (RGEN) Up 3.6% Since Last Earnings Report: Can It Continue?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 13h ago
Insider Sell: Repligen
MT Newswires · 1d ago
Repligen Corporation (NASDAQ:RGEN) Shares Could Be 40% Below Their Intrinsic Value Estimate
Today we will run through one way of estimating the intrinsic value of Repligen Corporation ( NASDAQ:RGEN ) by taking...
Simply Wall St. · 1d ago
Repligen Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at three upcoming investor conferences. Craig-Hallum’...
GlobeNewswire · 2d ago
Will Repligen's (RGEN) COVID Woes Be Offset by Product Demand?
The declining pace of COVID-19 vaccination programs is likely to hurt Repligen's (RGEN) revenue growth rate in 2022. However, the strong core business is likely to offer a respite.
Zacks · 05/16 13:41
We Think Repligen (NASDAQ:RGEN) Can Manage Its Debt With Ease
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Simply Wall St. · 05/12 12:43
Is it a Great Move to Invest in Repligen Corp. (RGEN)?
LRT Capital Management, an investment management firm, published its first-quarter 2022 investor letter – a copy of which can be downloaded here. A return of -7.37% was recorded by the LRT Economic Moat strategy for the first quarter of 2022, resulting in ...
Insider Monkey · 05/03 11:58
Repligen's Return On Capital Employed Insights
According to Benzinga Pro, during Q1, Repligen (NASDAQ:RGEN) earned $46.96 million, a 61.33% increase from the preceding quarter. Repligen also posted a total of $206.40 million in sales, a 10.66% increase since Q4.
Benzinga · 05/02 13:52
More
No Data
Learn about the latest financial forecast of RGEN. Analyze the recent business situations of Repligen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

44.44%Strong Buy
44.44%Buy
11.11%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RGEN stock price target is 239.88 with a high estimate of 320.00 and a low estimate of 170.00.
High320.00
Average239.88
Low170.00
Current 170.04
EPS
Actual
Estimate
0.230.460.690.92
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 575
Institutional Holdings: 57.77M
% Owned: 104.22%
Shares Outstanding: 55.43M
TypeInstitutionsShares
Increased
173
3.89M
New
42
478.96K
Decreased
136
1.97M
Sold Out
91
843.20K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.86%
Healthcare Equipment & Supplies
+2.75%
Key Executives
Non-Executive Chairman/Independent Director
Karen Dawes
President/Chief Executive Officer/Director
Anthony Hunt
Chief Financial Officer
Jon Snodgres
Chief Operating Officer
James Bylund
Senior Vice President
Christine Gebski
Senior Vice President
Ralf Kuriyel
Independent Director
Nicolas Barthelemy
Independent Director
Carrie Manner
Independent Director
Rohin Mhatre
Independent Director
Glenn Muir
Independent Director
Thomas Ryan
No Data
No Data
About RGEN
Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, Filtration; Chromatography; Process Analytics; and Proteins. The Filtration products are used in process development and process scale (clinical and commercial) production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market.

Webull offers kinds of Repligen Corporation stock information, including NASDAQ:RGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RGEN stock methods without spending real money on the virtual paper trading platform.